23/09/2026
Tutkijat ovat vihdoinkin sitä mieltä, että Alzheimeriin löytyy parannuskeino.
🧠 Alzheimer’s disease is no longer universally considered “untreatable,” according to the 2026 World Alzheimer Report.
The report argues that dementia research has entered a new era, driven by disease-modifying drugs, earlier diagnosis and growing evidence that some dementia risk can be reduced.
Two drugs, lecanemab and donanemab, have now shown that it is possible to modestly slow cognitive decline in some people with early Alzheimer’s disease.
These treatments target amyloid-beta, one of the abnormal proteins that builds up in the brain.
They are not cures, do not restore lost memory and do not work equally well for everyone.
But researchers say their biggest impact may be proving that the course of Alzheimer’s can be altered at all.
The treatment pipeline is also expanding rapidly.
According to the report, 158 potential therapies are currently being tested across 192 clinical trials worldwide, with more than a third originally developed for other conditions.
At the same time, prevention is becoming increasingly important.
Evidence suggests that addressing factors such as high blood pressure, smoking, diabetes, physical inactivity, depression, hearing loss and high cholesterol could delay or prevent a substantial proportion of dementia cases.
Better diagnosis may be just as important as new medicines.
Current disease-modifying drugs work best early, yet many people are diagnosed only after significant brain damage has already occurred.
Promising blood-based biomarker tests could eventually make earlier detection much easier.
There is still no cure for Alzheimer’s, and access to new treatments remains limited.
But after decades when doctors could do little beyond manage symptoms, researchers now have the first evidence that Alzheimer’s progression can be slowed — and many more approaches are being tested.
📃 MAJOR REPORT
📌 Alzheimer’s Disease International, “World Alzheimer Report 2026: A New Era in Dementia Clinical Trials” (2026)
